# Azora Therapeutics Inc. (AZR)

Source: https://www.quantisnow.com/company/AZR
Generated: 2026-11-17T16:57:13.861Z

- Ticker: AZR
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2018
- SEC CIK: 0001513525
- Website: https://www.adial.com

## About

Azora Therapeutics Inc. is a biopharmaceutical company focused on developing treatments for serious inflammatory diseases. The company was spun out of Stanford University after being incubated in the translational medicine SPARK program. Azora owns the worldwide royalty-free rights to its technology, which is based on the development of potential best-in-class oral agonists of the aryl hydrocarbon receptor. Azora's lead program is AT177, a proprietary colon-targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure in development for ulcerative colitis.

## Latest AZR news and filings

- 2026-11-17 02:45 UTC [SEC Form S-3] [SEC Form S-3 filed by Azora Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-3-filed-by-azora-therapeutics-inc-6795450)
- 2026-11-13 21:30 UTC [SEC Form S-8] [SEC Form S-8 filed by Azora Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-filed-by-azora-therapeutics-inc-6790961)
- 2026-11-12 21:06 UTC [SEC Form 8-K] [Azora Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/azora-therapeutics-inc-filed-sec-form-8-k-results-of-operations-6787846)
- 2026-11-12 21:05 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Azora Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-azora-therapeutics-inc-6787786)
- 2026-11-12 21:05 UTC [Earnings] [Azora Therapeutics Reports 2026 Third Quarter Financial Results and Provides Business Update](https://www.quantisnow.com/insight/azora-therapeutics-reports-2026-third-quarter-financial-results-and-provides-6787669)
- 2026-11-10 13:00 UTC [SEC Form 3] [SEC Form 3 filed by new insider Soloway Thomas M](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-soloway-thomas-m-6782996)
- 2026-11-10 13:00 UTC [SEC Form 3] [SEC Form 3 filed by new insider Hastings Paul J](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-hastings-paul-j-6782969)
- 2026-11-10 13:00 UTC [SEC Form 3] [SEC Form 3 filed by new insider Habtezion Aida](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-habtezion-aida-6782968)
- 2026-11-09 12:30 UTC [SEC Form 8-K] [Azora Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/azora-therapeutics-inc-filed-sec-form-8-k-leadership-update-other-6780224)
- 2026-11-05 12:00 UTC [Leadership Update] [Azora Therapeutics Appoints Board of Directors with Extensive Drug Development and Inflammatory Bowel Disease Expertise](https://www.quantisnow.com/insight/azora-therapeutics-appoints-board-of-directors-with-extensive-drug-development-6774385)
- 2026-11-04 21:54 UTC [SEC Form 4] [President and CEO Davidson Matt converted options into 626,252 shares, increasing direct ownership by 179% to 819,018 units (SEC Form 4)](https://www.quantisnow.com/insight/president-and-ceo-davidson-matt-converted-options-into-626252-shares-6773382)
- 2026-11-04 21:53 UTC [SEC Form 4] [Chief Strategy Officer Saiki Julie converted options into 626,252 shares, increasing direct ownership by 463% to 761,636 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-strategy-officer-saiki-julie-converted-options-into-626252-shares-6773376)
- 2026-11-03 19:30 UTC [SEC Form 4] [SEC Form 4 filed by Large owner Coastlands Capital Lp](https://www.quantisnow.com/insight/sec-form-4-filed-by-large-owner-coastlands-capital-lp-6769213)
- 2026-11-03 19:29 UTC [SEC Schedule 13G] [Amendment: SEC Form SCHEDULE 13G/A filed by Azora Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-azora-therapeutics-inc-6769211)
- 2026-11-02 12:35 UTC [Analyst Coverage Initiated] [TD Cowen initiated coverage on Aztar](https://www.quantisnow.com/insight/td-cowen-initiated-coverage-on-aztar-6766139)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/AZR
- Earnings history: https://www.quantisnow.com/earnings/AZR
- Dividend history: https://www.quantisnow.com/dividends/AZR
- Insider transactions: https://www.quantisnow.com/insiders/AZR
- Options chain: https://www.quantisnow.com/options/AZR
- SEC 8-K filings only: https://www.quantisnow.com/company/AZR/8-k
- RSS and alerts for AZR: https://www.quantisnow.com/docs/rss-feeds.md
